Chiasma Inc. Daily Stock Analysis

Daily Stock Analysis, CHMA, Chiasma Inc, priceseries

Chiasma Inc. Daily Stock Analysis
Stock Information
Open
3.76
Close
3.76
High
3.76
Low
3.76
Previous Close
3.76
Daily Price Gain
0.00
YTD High
5.00
YTD High Date
Feb 9, 2021
YTD Low
2.77
YTD Low Date
Mar 29, 2021
YTD Price Change
-0.54
YTD Gain
-12.56%
52 Week High
5.00
52 Week High Date
Feb 9, 2021
52 Week Low
2.77
52 Week Low Date
Mar 29, 2021
52 Week Price Change
-0.87
52 Week Gain
-18.79%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 23. 2017
1.90
Sep 7. 2017
2.12
10 Trading Days
11.62%
Link
LONG
Sep 11. 2017
2.15
Sep 26. 2017
2.37
11 Trading Days
10.25%
Link
LONG
Sep 27. 2017
2.45
Oct 11. 2017
2.68
10 Trading Days
9.29%
Link
LONG
Sep 13. 2018
2.60
Oct 2. 2018
3.28
13 Trading Days
26.02%
Link
LONG
Oct 30. 2018
3.64
Nov 12. 2018
3.98
9 Trading Days
9.25%
Link
LONG
Dec 28. 2018
2.98
Jan 30. 2019
3.50
21 Trading Days
17.56%
Link
LONG
Feb 13. 2019
3.70
Mar 20. 2019
5.97
24 Trading Days
61.36%
Link
LONG
Jun 4. 2019
6.88
Jun 20. 2019
7.80
12 Trading Days
13.37%
Link
LONG
Oct 15. 2019
4.84
Nov 8. 2019
5.21
18 Trading Days
7.58%
Link
LONG
Apr 24. 2020
4.59
May 13. 2020
5.24
13 Trading Days
14.25%
Link
LONG
Jun 23. 2021
4.22
Jul 6. 2021
4.52
8 Trading Days
7.05%
Link
Company Information
Stock Symbol
CHMA
Exchange
NasdaqGS
Company URL
http://www.chiasmapharma.com
Company Phone
617-928-5300
CEO
Mark J. Fitzpatrick
Headquarters
Massachusetts
Business Address
275 WYMAN STREET, SUITE 250, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001339469
About

Chiasma, Inc. operates as a pharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin on April 12, 2001 and is headquartered in Waltham, MA.

Description

Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading